Zielinski Valerie, Laban Simon, Tribius Silke, Schafhausen Phillipe, Veldhoen Simon, Knecht Rainald, Clauditz Till, Muenscher Adrian
Department of Otorhinolaryngology-Head and Neck Surgery, Krankenhaus Rudolfstiftung, Juchgasse 25, 1030 Vienna, Austria.
Ear Nose Throat J. 2016 Jan;95(1):23-8.
Sinonasal undifferentiated carcinoma (SNUC) represents less than 1% of all malignancies. Most of the tumors are diagnosed at an advanced stage, when they have already invaded neighboring tissue structures. We describe the cases of 2 patients with a substantial intracerebral extension of SNUC who were treated at our institution. One was treated with surgery followed by chemoradiotherapy. The other was primarily treated with induction chemotherapy with a combination of docetaxel, cisplatin, and 5-fluorouracil followed by concurrent chemo- and radiotherapy. In view of the rarity of SNUC, no prospective clinical trials have been performed and a gold standard for treatment has not yet been established. Therefore, treatment recommendations are based on level IV evidence. These recommendations are diverse and controversial. In our 2 cases, the patient who was treated with induction chemotherapy had a better outcome. In cases of intracerebral extension, radical surgery is necessary and induction chemotherapy should be considered.
鼻窦未分化癌（SNUC）占所有恶性肿瘤的比例不到1%。大多数此类肿瘤在晚期才被诊断出来，此时它们已经侵犯了邻近的组织结构。我们描述了在我院接受治疗的2例SNUC伴有大量脑内扩展的病例。1例接受了手术治疗，随后进行放化疗。另1例首先接受了多西他赛、顺铂和5-氟尿嘧啶联合诱导化疗，随后进行同步放化疗。鉴于SNUC的罕见性，尚未进行前瞻性临床试验，也尚未确立治疗的金标准。因此，治疗建议基于四级证据。这些建议多种多样且存在争议。在我们的2例病例中，接受诱导化疗的患者预后较好。对于脑内扩展的病例，根治性手术是必要的，应考虑诱导化疗。
